Latest common stock for PNT: $11K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
POINT Biopharma Global (PNT) currently reports a common stock of $11K as of September 2023. That compares with $92M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore POINT Biopharma Global's common stock history and peer comparisons.
POINT Biopharma Global's common stock decreased from $92M to $11K — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
POINT Biopharma Global reported $11K in common stock as of September 2023. That compares with $92M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $11K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for POINT Biopharma Global, and consider following PNT for alerts when major investors trade the stock.
POINT Biopharma Global is classified in the Healthcare sector. On common stock, it currently shows $11K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PNT with unrelated industries.